company background image
NRXP

NRx Pharmaceuticals NasdaqGM:NRXP Stock Report

Last Price

US$1.42

Market Cap

US$96.1m

7D

-4.1%

1Y

-75.4%

Updated

08 Dec, 2022

Data

Company Financials +
NRXP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NRXP Stock Overview

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.

NRx Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NRx Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.42
52 Week HighUS$6.33
52 Week LowUS$0.49
Beta0.91
1 Month Change66.10%
3 Month Change102.83%
1 Year Change-75.43%
3 Year Change-86.78%
5 Year Change-85.36%
Change since IPO-85.21%

Recent News & Updates

Recent updates

Shareholder Returns

NRXPUS PharmaceuticalsUS Market
7D-4.1%-0.3%-2.8%
1Y-75.4%14.1%-19.6%

Return vs Industry: NRXP underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.

Return vs Market: NRXP underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is NRXP's price volatile compared to industry and market?
NRXP volatility
NRXP Average Weekly Movement12.6%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: NRXP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: NRXP's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015n/aSteve Willardhttps://www.nrxpharma.com

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

NRx Pharmaceuticals, Inc. Fundamentals Summary

How do NRx Pharmaceuticals's earnings and revenue compare to its market cap?
NRXP fundamental statistics
Market CapUS$96.05m
Earnings (TTM)-US$315.74m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NRXP income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$315.74m
Earnings-US$315.74m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-4.67
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did NRXP perform over the long term?

See historical performance and comparison